Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Human Albumin 20% IV infusion

Marketed by Dexa Medica

Ingredients in every 100 ml

Human Albumin 20000 mg

Each package contains

1 bottle of 100 ml

Dosage form

IV infusion

Dosage formIntravenous infusion

Flavour

None

W.H.O. classification

B05A
B05A

A.T.C. Level 1

Anatomical Main group

B - Blood and blood forming organs
B05A

A.T.C. Level 2

Therapeutic subgroup

B05 - Blood Substitutes and Perfusion Solutions
B05A

A.T.C. Level 3

Pharmacological subgroup

B05A - Blood and Related Products

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

SAFE IF PRESCRIBEDThis item is safe for use while operating heavy machinery.

Pregnancy

SAFE IF PRESCRIBEDThis item is safe for use during pregnancy.

Lactation

SAFE IF PRESCRIBEDThis item is safe for use during lactation.

Indication

Increase in oncotic pressure in case of oncotic deficiency. Diluted as a 4-5% solution for iso-oncotic volume replacement with long-term effect. Therapy of albumin deficiency.

Dosage

FOR ALL AGES
Human albumin can be administered by the intravenous route, either undiluted or after dilution in an isotonic solution (e.g. 5% glucose or 0.9 % sodium chloride).

Albumin solutions must not be diluted with water for injections as this may cause haemolysis in recipients. The infusion rate should be adjusted according to the individual circumstances and the indication.

In plasma exchange the infusion-rate should be adjusted to the rate of removal. If large volumes are administered, the product should be warmed to room or body temperature before use. Do not use solutions which are cloudy or contain residues (deposits/particles). This may indicate that the protein is unstable or that the solution has become contaminated

OTHER DETAILS
The dose required depends on the size of the patient, the severity of trauma or illness and on continuing fluid and protein losses. Measures of adequacy of circulating volume and not plasma albumin levels should be used to determine the dose required.
If human albumin is to be administered, hemodynamic performance should be monitored regularly; this may include:
– arterial blood pressure and pulse rate
– central venous pressure
– pulmonary artery wedge pressure
– urine output
– electrolyte
– haematocrit/haemoglobin